Tavotek Biotherapeutics Doses First Subject in Phase 1 First-in-Human Clinical Trial of TAVO412, a Multispecific Biologic for Solid Tumors

May 9, 2023 at 8:00 AM EST

Lower Gwynedd, Pennsylvania – May 9^th, 2023 – Tavotek Biotherapeutics announced today that its multispecific antibody, TAVO412, has been successfully dosed in its first patient at Mount Sinai Hospital in New York City, NY. TAVO412 is a first-in-class multispecific antibody developed for patients with solid tumors.

This study, termed TAVO412-0001, is a 2-part, open-label, dose-escalation and dose-expansion, Phase 1 evaluation of the safety, tolerability, MTD/RP2D, immunogenicity, and PK/PD in patients with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy.

Dr. Mann Fung, CEO said, “We are thrilled to announce that we have dosed our first patient in our Phase 1 oncology study. Thanks to our dedicated team, we are one step closer to potentially life-changing therapies for cancer patients. We remain committed to advancing our pipeline and bringing innovative treatments to those in need.”

“We are excited to see our novel approach to cancer therapy move into the clinical trial phase and look forward to the data that will be generated. Our hope is that this drug demonstrates both its safety and promising efficacy results that will provide a significant benefit to cancer patients,” said Dr. Mark Chiu, Chief Scientific Officer. “We remain committed to advancing science and developing new therapies to address unmet medical needs. Our team will continue to work diligently to ensure the success of this study and bring hope to patients fighting cancer.”

Tavotek currently has two immunology assets, TAVO101 and TAVO103A, that have completed dosing and are expected to wrap up their Phase 1 trials later this year. TAVO103A is a best-in-class human monoclonal antibody developed for chronic inflammation. TAVO101 is a humanized monoclonal antibody developed for various kinds of allergies.

About Tavotek

Tavotek is a clinical-stage biopharmaceutical enterprise that strives to improve the lives of patients grappling with severe and complex medical conditions by developing, acquiring, and bringing to market innovative therapeutic drugs. Tavotek has three diverse R&D platform for biologics: TavoSelect™ (Phage Display Library), TavoPrecise™ (Tissue-specific biologics engineering platform), and TavoELITE™ (Intracellular Undruggable Target platform). These platforms contribute to a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, inflammatory diseases, and other debilitating diseases with significant unmet medical needs. For more information, please visit www.tavotek.com.

Tavotek Contact:

Isa Fung, Media Relations

Email: info@tavotek.com